Got this in my inbox in the past few days. Don't know much about it or if it could help someone, but thought I would pass it along just in case.
Lee
Medical research study for metastatic colorectal cancer patients enrolling now
The XilonixTM Colon cancer Immunotherapy Treatment Evaluation (XCITE) medical research study to evaluate XBiotech's True HumanTM monoclonal antibody treatment for metastatic colorectal cancer is currently enrolling patients. To learn more and see if you may qualify, click here.
The primary objective of the XCITE clinical trial in colon cancer is to assess the ability of XilonixTM (the “study drug”) to improve the overall survival in patients with metastatic colorectal cancer who are refractory to standard therapy. XilonixTM contains an antibody (a protein that binds to a substance related to the disease). By binding to this substance, XilonixTM may help to inhibit tumor growth and spread of the cancer by interrupting crucial signals that drive the formation of new blood vessels, especially blood vessels that supply oxygen and nutrients to cancerous tissue and facilitate spread of the cancer. In addition XilonixTM may help to correct fatigue, muscle loss and anxiety caused from tumor related inflammation.
XCITE is an investigational study. XilonixTM (the “study drug”) is not approved by the U.S. Food and Drug Administration (FDA) or commercially available in the United States. It is currently being used for research purposes only.
You may be eligible to participate in this study if you:
Are 18 years of age or older
Have metastatic colorectal cancer refractory to standard therapy
Do not have any other serious or uncontrolled medical conditions.
If enrolled, the length of time you will be asked to participate in this study depends on how your cancer responds to the study treatment.
To learn more and see if you may qualify, click here.
To unsubscribe, click here.